After oral administration, it can form a protective film on the gastric mucosa and stimulate the gastric mucosal epithelial cells to secrete mucus, increasing the protective effect on the mucosa. In addition, it can kill Helicobacter pylori and promote the healing of gastritis.

This product has good antibacterial effect on superficial fungi such as Trichophyton, Microsporum, Epidermophyton, etc. It has no antibacterial effect on Candida, Cryptococcus, Histoplasma, Sporothrix, Blastomyces, Coccidioides, etc. This drug inhibits the growth of fungi by interfering with the synthesis of fungal nucleic acids.

A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.

This product is a broad-spectrum semi-synthetic penicillin with extremely low toxicity. The antibacterial spectrum is similar to that of penicillin, and it has a strong antibacterial effect on grass-green streptococci, hemolytic streptococci, and enterococci. Diphtheria bacillus, anthrax bacillus, Gram-positive anaerobic cocci and bacilli are sensitive to this product; meningococci, pertussis bacilli, and Brucella are also very sensitive. Escherichia coli, Salmonella, Shigella dysenteriae, Proteus, influenza bacilli, pneumococci, gonococci, etc., all have varying degrees of drug resistance because some strains produce beta-lactamase. Among them, the resistance rate of Escherichia coli is as high as 50-60%. Enterobacter bacteria, Pseudomonas aeruginosa, and anaerobic Gram-negative bacilli are resistant to this product. This product is mainly used to treat infectious diseases caused by sensitive Staphylococcus aureus, hemolytic streptococci, gonococci, meningococci and diphtheria Bordetella, pertussis Bordetella, influenza Bordetella, Salmonella, Shigella, etc.; such as respiratory tract infections (pneumonia, acute and chronic bronchitis, whooping cough, etc.), gastroenteritis and digestive tract infections (liver and gallbladder infections, acute and chronic gastroenteritis, bacillary dysentery, typhoid and paratyphoid, etc.), urinary tract infections (gonorrhea, urethritis, cystitis, etc.), soft tissue infections and sepsis, meningitis, endocarditis, etc.

It acts on the second step of folic acid anabolism and selectively inhibits the action of dihydrofolate reductase. When used in combination with sulfamethoxazole, it can double-block the bacterial folic acid metabolism, enhance the synergistic antibacterial effect, and reduce drug-resistant strains.

It acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis. When used in combination with trimethoprim, it can doubly block the bacterial folic acid metabolism, enhance the synergistic antibacterial effect, and reduce drug-resistant strains.